CF
COGT icon

Cantor Fitzgerald’s Cogent Biosciences COGT Stock Holding History

Cantor Fitzgerald’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.35M Buy
+35,000
New +$1.22M 0.01% 214

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Cantor Fitzgerald's COGT Position: Q2 2026 in Review

Cantor Fitzgerald opened a new position in Cogent Biosciences (COGT) in Q2 2026: 35,000 shares worth $1.35M. The stake represents 0.01% of the portfolio and ranks #214 among its holdings.

322 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Cantor Fitzgerald held 35,000 shares of Cogent Biosciences worth $1.35M as of Q2 2026.
  • Cogent Biosciences was a new Cantor Fitzgerald position in Q2 2026.
  • Cogent Biosciences made up 0.01% of Cantor Fitzgerald's portfolio in Q2 2026, its #214 holding.
  • 322 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Cantor Fitzgerald's 13F filing for Q2 2026, filed 14 Aug 2026.